Published in JAMA on October 20, 2010
Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst (2011) 4.14
The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause (2012) 4.04
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. JAMA Oncol (2015) 3.64
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
Progesterone receptor modulates ERα action in breast cancer. Nature (2015) 2.85
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer (2013) 2.60
Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst (2013) 2.45
Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst (2013) 2.21
Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med (2014) 2.20
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Sex hormone levels and risk of breast cancer with estrogen plus progestin. J Natl Cancer Inst (2013) 1.60
Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer (2013) 1.54
Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2012) 1.53
Knowledge, perceptions and information about hormone therapy (HT) among menopausal women: a systematic review and meta-synthesis. PLoS One (2011) 1.48
Breast Cancer Risk - Genes, Environment and Clinics. Geburtshilfe Frauenheilkd (2011) 1.47
Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women. J Natl Cancer Inst (2015) 1.44
Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial. J Natl Cancer Inst (2015) 1.41
Screening mammography use among current, former, and never hormone therapy users may not explain recent declines in breast cancer incidence. Cancer Epidemiol Biomarkers Prev (2012) 1.39
Changing concepts: Menopausal hormone therapy and breast cancer. J Natl Cancer Inst (2012) 1.39
Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res (2012) 1.37
Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat (2012) 1.31
How I treat late effects in adults after allogeneic stem cell transplantation. Blood (2010) 1.26
Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol (2011) 1.23
The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet (2012) 1.23
Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev (2012) 1.20
The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol (2011) 1.19
Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev (2014) 1.17
Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab (2011) 1.12
Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes. PLoS One (2012) 1.09
Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res (2012) 1.08
Promotional tone in reviews of menopausal hormone therapy after the Women's Health Initiative: an analysis of published articles. PLoS Med (2011) 1.07
Postmenopausal hormone therapy and breast cancer: an uncertain trade-off. JAMA (2010) 1.05
Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. PLoS One (2014) 1.05
Hot flashes: a review of pathophysiology and treatment modalities. Oncologist (2011) 1.02
Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1/DUSP1). J Biol Chem (2011) 1.00
Estrogen plus progestin and colorectal cancer incidence and mortality. J Clin Oncol (2012) 1.00
Amphiregulin mediates estrogen, progesterone, and EGFR signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers. Horm Cancer (2010) 0.99
Preventive effects of phytoestrogens against postmenopausal osteoporosis as compared to the available therapeutic choices: An overview. J Nat Sci Biol Med (2011) 0.96
Progesterone and Overlooked Endocrine Pathways in Breast Cancer Pathogenesis. Endocrinology (2015) 0.96
Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. Breast Cancer Res (2014) 0.95
From the ranks of mammary progesterone mediators, RANKL takes the spotlight. Mol Cell Endocrinol (2011) 0.94
Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol Cell Endocrinol (2011) 0.93
Postmenopausal hormone therapy: risks and benefits. Nat Rev Endocrinol (2013) 0.93
High burden of breast cancer in Belgium: recent trends in incidence (1999-2006) and historical trends in mortality (1954-2006). Arch Public Health (2011) 0.93
Progesterone receptor action: defining a role in breast cancer. Expert Rev Endocrinol Metab (2011) 0.92
Molecular determinants of context-dependent progesterone receptor action in breast cancer. BMC Med (2014) 0.92
Tracking progesterone receptor-mediated actions in breast cancer. Pharmacol Ther (2013) 0.91
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prev Res (Phila) (2011) 0.90
Effect of a combination of genistein, polyunsaturated fatty acids and vitamins D3 and K1 on bone mineral density in postmenopausal women: a randomized, placebo-controlled, double-blind pilot study. Eur J Nutr (2013) 0.89
The TU-025 keishibukuryogan clinical trial for hot flash management in postmenopausal women: results and lessons for future research. Menopause (2011) 0.89
Hormone therapy, estrogen metabolism, and risk of breast cancer in the Women's Health Initiative Hormone Therapy Trial. Cancer Epidemiol Biomarkers Prev (2012) 0.89
Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Horm Cancer (2012) 0.88
Aging, Angiotensin system and dopaminergic degeneration in the substantia nigra. Aging Dis (2011) 0.88
Elevation of SIPL1 (SHARPIN) Increases Breast Cancer Risk. PLoS One (2015) 0.88
Does equol production determine soy endocrine effects? Eur J Nutr (2012) 0.87
Progestin effects on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res (2013) 0.87
Breast cancer subtypes in Asian-Americans differ according to Asian ethnic group. J Immigr Minor Health (2012) 0.87
Progestin modulates the lipid profile and sensitivity of breast cancer cells to docetaxel. Mol Cell Endocrinol (2012) 0.87
Demographic and health factors associated with enrollment in posttrial studies: the Women's Health Initiative Hormone Therapy Trials. Clin Trials (2013) 0.86
Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses' health studies. Int J Cancer (2016) 0.86
Knowledge, attitude and practice of breast self-examination among female undergraduate students in the University of Buea. BMC Res Notes (2015) 0.84
Retracted Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert Opin Pharmacother (2011) 0.83
Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease. Am J Neurodegener Dis (2012) 0.83
A multimineral natural product from red marine algae reduces colon polyp formation in C57BL/6 mice. Nutr Cancer (2012) 0.83
Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev (2012) 0.83
Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008). Dis Esophagus (2013) 0.83
The association between the 844ins68 polymorphism in the CBS gene and breast cancer. Arch Med Sci (2014) 0.82
Menopausal hormone therapy and cancer: changing clinical observations of target site specificity. Steroids (2014) 0.82
The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development. Int J Oncol (2012) 0.82
Apigenin prevents development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats. Cancer Prev Res (Phila) (2011) 0.82
Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke. Semin Reprod Med (2014) 0.82
Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. Menopause (2012) 0.82
Epithelial-Mesenchymal Transition (EMT) and Regulation of EMT Factors by Steroid Nuclear Receptors in Breast Cancer: A Review and in Silico Investigation. J Clin Med (2016) 0.81
A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication. Breast Cancer Res Treat (2013) 0.81
Major clinical research advances in gynecologic cancer in 2015. J Gynecol Oncol (2016) 0.81
Progesterone receptor isoforms PRA and PRB differentially contribute to breast cancer cell migration through interaction with focal adhesion kinase complexes. Mol Biol Cell (2013) 0.80
An update on hormone replacement therapy: health and medicine for women: a multidisciplinary, evidence-based review of mid-life health concerns. Yale J Biol Med (2011) 0.80
Pre-diagnosis oophorectomy, estrogen therapy and mortality in a cohort of women diagnosed with breast cancer. Breast Cancer Res (2013) 0.80
MODELLING COUNTY LEVEL BREAST CANCER SURVIVAL DATA USING A COVARIATE-ADJUSTED FRAILTY PROPORTIONAL HAZARDS MODEL. Ann Appl Stat (2015) 0.80
Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy. Breast Cancer Res Treat (2014) 0.80
Labisia pumila Prevents Complications of Osteoporosis by Increasing Bone Strength in a Rat Model of Postmenopausal Osteoporosis. Evid Based Complement Alternat Med (2012) 0.80
Postmenopausal hormone therapy and breast cancer risk: current status and unanswered questions. Endocrinol Metab Clin North Am (2011) 0.80
Steroid Hormones, Steroid Receptors, and Breast Cancer Stem Cells. J Mammary Gland Biol Neoplasia (2015) 0.80
New antiresorptive therapies for postmenopausal osteoporosis. J Menopausal Med (2015) 0.79
Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast. Int J Womens Health (2013) 0.79
Hormonal therapy and risk of breast cancer in mexican women. PLoS One (2013) 0.79
Tissue selective estrogen complexes (TSECs) differentially modulate markers of proliferation and differentiation in endometrial cells. Reprod Sci (2012) 0.79
Folic acid supplementation improves vascular function in professional dancers with endothelial dysfunction. PM R (2011) 0.79
Age-dependent Effects of 17β-estradiol on the dynamics of estrogen receptor β (ERβ) protein-protein interactions in the ventral hippocampus. Mol Cell Proteomics (2014) 0.79
Association of type 2 diabetes genetic variants with breast cancer survival among Chinese women. PLoS One (2015) 0.78
Endocrine disrupting activities of the flavonoid nutraceuticals luteolin and quercetin. Horm Cancer (2013) 0.78
Phytoestrogen α-zearalanol ameliorates memory impairment and neuronal DNA oxidation in ovariectomized mice. Clinics (Sao Paulo) (2013) 0.77
Down-regulation of serum gonadotropins but not estrogen replacement improves cognition in aged-ovariectomized 3xTg AD female mice. J Neurochem (2014) 0.77
Estrogen receptor modulatory effects of germinated brown rice bioactives in the uterus of rats through the regulation of estrogen-induced genes. Drug Des Devel Ther (2013) 0.77
Incidence and mortality rates in breast, corpus uteri, and ovarian cancers in Poland (1980-2013): an analysis of population-based data in relation to socioeconomic changes. Onco Targets Ther (2016) 0.77
The tissue selective estrogen complex: a promising new menopausal therapy. Pharmaceuticals (Basel) (2012) 0.76
Modulation of higher-primate adrenal androgen secretion with estrogen-alone or estrogen-plus-progesterone intervention. Menopause (2013) 0.76
Functional maintenance of differentiated embryoid bodies in microfluidic systems: a platform for personalized medicine. Stem Cells Transl Med (2015) 0.76
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials (1998) 20.39
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med (1991) 19.46
Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet (2003) 18.24
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68
Implementation of the Women's Health Initiative study design. Ann Epidemiol (2003) 7.30
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med (2010) 4.27
Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst (2005) 4.01
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol (2007) 3.46
Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol (2008) 2.79
Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol (2003) 2.02
Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol (2006) 1.96
Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med (2008) 1.94
Attitudes of obstetrician-gynecologists toward the evidence from the Women's Health Initiative hormone therapy trials remain generally skeptical. Menopause (2009) 1.80
Estrogen and angiogenesis: A review. Arterioscler Thromb Vasc Biol (2001) 1.76
The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival. Am J Surg (2009) 1.72
Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer (2004) 1.56
Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res (2008) 1.53
Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol (2009) 1.52
Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene (2008) 1.48
Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res (1998) 1.44
Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res (2007) 1.31
Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas (2006) 1.31
Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias. Epidemiology (2001) 1.28
Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.25
Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Breast Cancer Res (2008) 1.16
Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol (1998) 1.13
Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev (2008) 1.12
[The role of estrogens in angiogenesis in the female reproductive system]. Endokrynol Pol (2009) 1.05
Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up. Am J Surg (2008) 1.02
Coronary heart disease and menopause management: the swinging pendulum of HRT. Atherosclerosis (2009) 0.94
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
Long-term exposure to air pollution and incidence of cardiovascular events in women. N Engl J Med (2007) 14.90
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab (2010) 13.29
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA (2004) 11.69
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA (2003) 10.05
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97
Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials (2005) 9.57
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med (2003) 9.24
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med (2004) 8.63
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med (2002) 7.77
National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68
The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol (2003) 7.49
A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care (2003) 7.40
Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Implementation of the Women's Health Initiative study design. Ann Epidemiol (2003) 7.30
Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51